An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Cerus Corporation to Participate in Upcoming Investor Conferences
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Cerus Corporation (CERS) will have management participation in two upcoming investor conferences, the BTIG 11th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 13th and TD Cowen’s 44th Annual Health Care Conference on March 6th. The company will also have a live webcast of the TD Cowen presentation, with a replay available on their website after the event.
Positive
None.
Negative
None.
CONCORD, Calif.--(BUSINESS WIRE)--
Cerus Corporation (Nasdaq: CERS) announced management participation in two upcoming investor conferences.
Management plans to attend the BTIG 11th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Tuesday, February 13th and will participate in TD Cowen’s 44th Annual Health Care Conference on Wednesday, March 6th at 11:10 AM EST.
A live webcast of the TD Cowen presentation will be available here and the replay will be available on the Company’s website after the event.
ABOUT CERUS
Cerus Corporation is dedicated solely to safeguarding the world’s blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, California, the company develops and supplies vital technologies and pathogen-protected blood components to blood centers, hospitals, and ultimately patients who rely on safe blood. The INTERCEPT Blood System for platelets and plasma is available globally and remains the only pathogen reduction system with both CE mark and FDA approval for these two blood components. The INTERCEPT red blood cell system is under regulatory review in Europe, and in late-stage clinical development in the U.S. Also in the U.S., the INTERCEPT Blood System for Cryoprecipitation is approved for the production of Pathogen Reduced Cryoprecipitated Fibrinogen Complex (commonly referred to as INTERCEPT Fibrinogen Complex), a therapeutic product for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. For more information about Cerus, visit www.cerus.com and follow us on LinkedIn.
INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.
When is Cerus Corporation (CERS) participating in the BTIG 11th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference?
Cerus Corporation (CERS) is participating in the BTIG 11th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Tuesday, February 13th.
What time will Cerus Corporation (CERS) participate in TD Cowen’s 44th Annual Health Care Conference?
Cerus Corporation (CERS) will participate in TD Cowen’s 44th Annual Health Care Conference on Wednesday, March 6th at 11:10 AM EST.
Will there be a webcast of the TD Cowen presentation by Cerus Corporation (CERS)?
Yes, there will be a live webcast of the TD Cowen presentation by Cerus Corporation (CERS), with a replay available on their website after the event.
